Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

16 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • (a) Validation of the global proteome and acetylome results. AS and BE2 cells were treated with 10 μM of perifosine for 16 h. Total proteins were extracted and 30 μg of protein was analyzed for integrin β5 and acetyl-Histone H2B (Lys12) by western blotting. GAPDH was used as loading control.

    Sci Rep, 2017, 7:41950. Perifosine (KRX-0401) purchased from Selleck.

    Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

  • Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

    Established cell lines (A549 and H460 lines) were un-stimulated (“C”, same for all figures), or treated with indicated concentration of perifosine (0.3-10 μM) or plus ABT-737 (100 nM), cells were then cultured for indicated time, and cell growth was tested by MTT assay (a, b, d, e) or by colony formation assay (c and f). “Prf” stands for perifosine (Same for all figures). The results presented were representative of three independent experiments. The values were expressed as the means ± SD. *p < 0.05 vs “C” group. #p < 0.05 compared with the perifosine only group without ABT-737 co-treatment.

    Biochem Biophys Res Commun, 2016, 473(4):1170-6. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  M4D6UWZ2dmO2aX;uJGF{e2G7 M{L3SVAvPS9zL{KuOUDPxE1? MmLxN{Bp NGracWpz\WS3Y3XzJJRp\SCkYYPhcEBESiC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUiyOlA6Pzh5Mx?=
T24 BC  M{DKd2NmdGxiVnnhZoltcXS7IFHzd4F6 MnHwNE42NzFxMj61JO69VQ>? NFnOWHczPCCq NXXKXnkx\W6qYX7j[ZMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDD2bYFjcWyrdImg[IVkemWjc3W= M1jR[|I3ODl5OEez
T24 BC  NVPYdGZQSXCxcITvd4l{KEG|c4PhfS=> NHz0Xm4zNjVizszN MmHmNlQhcA>? MmnUd4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= NYm3WGdxOjZyOUe4O|M>
HepG2 MYDGeY5kfGmxbjDBd5NigQ>? M2r2TVIxyqEQvF2= NYDUV4sxOjUEoHi= MY\wdo9lfWOnczDhckBqdnSnboPlJIN6fG:ybHHzcYlkKH[jY4XvcIl7[XSrb36gZ49zemW|cH;u[Ilv\yC2bzDhJI5wfGGkbHWg[Ilt[XSjdHnvckBw\iC2aHWgSXIh[2m|dHXycpM> NELCOWgzPTl|NEKzNi=>
U-87 MG  NFHXcpNHfW6ldHnvckBCe3OjeR?= MkSwNlDDqM7:TR?= M17yflI1yqCq NYPp[48ycW6lcnXhd4V{KGSxdXLs[U1u\W2kcnHu[UBjd3WwZDDzeJJ2[3S3cnXz NUWwbZJLOjV7M{SyN|I>
HepG2 NW\oSll[TnWwY4Tpc44hSXO|YYm= MWeyNOKh|ryP M1;lSFYwOjRiaB?= MoHpbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MWmyOVk{PDJ|Mh?=
U-87 MG  MknISpVv[3Srb36gRZN{[Xl? NGjrW4kzOMLizszN MUS2M|I1KGh? NUHlXoxZcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gUGM{NUmLIHPveJJm[XSnZDD3bZRpKEOT MXGyOVk{PDJ|Mh?=
HepG2 NXnxV|JsTnWwY4Tpc44hSXO|YYm= MUCyNOKh|ryP M3XqS|YwOjRiaB?= MUPk[YNz\WG|ZYOgUGM{NUmLIHTl[5Ji\GG2aX;uxsBnem:vIE[gbC=> NHHLSWozPTl|NEKzNi=>
U-87 MG  MXnGeY5kfGmxbjDBd5NigQ>? MYmyNOKh|ryP MUW2M|I1KGh? MUDpcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? MorYNlU6OzR{M{K=
HepG2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fVd|IxNzRyIN88US=> NFLJdHQzPC92ODDo MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NH\qeWQzPTl|NEKzNi=>
U-87 MG  Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LjblIxNzRyIN88US=> NVr0RmVCOjRxNEigbC=> NHftU5BqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MUWyOVk{PDJ|Mh?=
A549 NFn6S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYiwMlMuOTBizszN NXPX[mhYOjRxN{KgbC=> MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M2r1cFI2Pjl5OEm5
H460 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW4VmIxNjNvMUCg{txO NYrHd2t4OjRxN{KgbC=> Mk\mbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4DFUVI2Pjl5OEm5
A549 NV\MfIpjSXCxcITvd4l{KEG|c4PhfS=> MmfFNU8{KM7:TR?= NU[wb2pmPDhiaB?= NVXCO5lNcW6mdXPld{BieG:ydH;zbZM> NHmzUXUzPTZ7N{i5PS=>
H460 NED0cXRCeG:ydH;zbZMhSXO|c3H5 M1TPRlEwOyEQvF2= MWG0PEBp NIruVoFqdmS3Y3XzJIFxd3C2b4Ppdy=> NITySFczPTZ7N{i5PS=>
A549 M1L3RWZ2dmO2aX;uJGF{e2G7 M2f6TVMh|ryP NHzkZYI5KGh? NFnwNotjdG:la4OgRWtVKGGldHn2ZZRqd25? M{PjdFI2Pjl5OEm5
H460 MVPGeY5kfGmxbjDBd5NigQ>? M17PNFMh|ryP NXrUWoVxQCCq MnrJZoxw[2u|IFHLWEBi[3SrdnH0bY9v MXiyOVY6Pzh7OR?=
A549 MXvGeY5kfGmxbjDBd5NigQ>? NE\JWlU{KM7:TR?= NXnWfZpSQCCq M4LYeoJtd2OtczDtWG9TSzFuIHHu[EBGWktvTVHQT{Bi[3SrdnH0bY9vKGOxbXLpcoVlKHerdHigUWVMNTF4Mh?= Mk\0NlU3QTd6OUm=
H460 Mn34SpVv[3Srb36gRZN{[Xl? MkPpN{DPxE1? MYi4JIg> MXLicI9kc3NibWTPVmMyNCCjbnSgSXJMNU2DUFugZYN1cX[jdHnvckBkd22kaX7l[EB4cXSqIF3FT{0yPjJ? M1nzZ|I2Pjl5OEm5
RMG1 M4XofGNmdGxiVnnhZoltcXS7IFHzd4F6 NF:0bGQyNTNyIN88US=> NUL4c|liPzJiaB?= M2TDOIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4LDSVI2PTF7MUS4
RMG2 Mon0R4VtdCCYaXHibYxqfHliQYPzZZk> MYCxMVMxKM7:TR?= NVnDbVY6PzJiaB?= MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NX;M[45wOjV3MUmxOFg>
KOC7C NH3zbItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWHESXlHOS1|MDFOwG0> NFGz[Y04OiCq M2XDW4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MYeyOVUyQTF2OB?=
HAC2 M3nYUGNmdGxiVnnhZoltcXS7IFHzd4F6 MmnINU0{OCEQvF2= MnTLO|IhcA>? NGe2PVNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NHzhR44zPTVzOUG0PC=>
RMG2 MmT2R4VtdCCYaXHibYxqfHliQYPzZZk> NHvye3gyNTNyIN88US=> NYjFWHliPDhiaB?= NYfsZ|Ay\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYLtXIxPOjV3MUmxOFg>
OVISE M1fXZ2NmdGxiVnnhZoltcXS7IFHzd4F6 M2PMdFEuOzBizszN MX20PEBp MnrJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NXTVSWZ4OjV3MUmxOFg>
SKOV3 MnfrR4VtdCCYaXHibYxqfHliQYPzZZk> NUnWWVA6OS1|MDFOwG0> M1ToOFQ5KGh? MlW2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NIDOV5kzPTVzOUG0PC=>
A2780 MofGR4VtdCCYaXHibYxqfHliQYPzZZk> M135NVEuOzBizszN NY\neYdXPDhiaB?= MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlqwNlU2OTlzNEi=
RMG1 NGnBemNCeG:ydH;zbZMhSXO|c3H5 M4THWFMxKM7:TR?= MXqyOEBp MVHpcoR2[2W|IHHwc5B1d3Orcx?= Mn;UNlU2OTlzNEi=
RMG2 NXf5VnhRSXCxcITvd4l{KEG|c4PhfS=> M4OzSlMxKM7:TR?= NGnicIIzPCCq NYL2SWpWcW6mdXPld{BieG:ydH;zbZM> Mo[4NlU2OTlzNEi=
HCC1806 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG2cnAxNTFyIN88US=> NFHmWZk1QCCq MXXFR|UxRTJwOEVihKnDueLCiUCuNFch|ryP NGr5XpIzPTJ7M{W3Oi=>
MDA-MB-231  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;mZnVqOC1zMDFOwG0> NEnicoY1QCCq MmS3SWM2OD1zLkGz5qCKyrIkgJmwMlA4KM7:TR?= Mn\YNlUzQTN3N{[=
GL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOwMlHjiJNzMEFihKnPxE1? NGfHd3o1QCCq MUTJR|UxRTlwOUGg{txO MXOyOFg5OTVyOB?=
CLBL-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDTNE4y6oDVMUCw5qCK|ryP M3XxfVQ5KGh? MXjJR|UxRTN|LkCg{txO M3vuRlI1QDhzNUC4
UL-1 M4X4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvsb|IxNjIkgKOxNFDjiIoQvF2= NIL6U5U1QCCq NWm0XZZVUUN3ME23MlAyKM7:TR?= MXeyOFg5OTVyOB?=
Ema MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[wMlHjiJNzMEFihKnPxE1? MX[0PEBp M{D5WGlEPTB;NUiuO{DPxE1? NV\Gd3N3OjR6OEG1NFg>
PANC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PxNlAuOjVizszN M2fPbFczKGh? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NWrWdG1oOjR3MUm3OVE>
MIA MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi1Ono3OC1{NTFOwG0> NUL0eHJkPzJiaB?= NI\1N|JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGnxU|IzPDVzOUe1NS=>
AsPC-1 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13LVlAuOjVizszN NETie2Q4OiCq MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYWyOFUyQTd3MR?=
PANC-1 MoDlSpVv[3Srb36gRZN{[Xl? M2jpVVAvPSEQvF2= NFXuR|AzPCCq Mke3bY5pcWKrdIOgRYt1NCCVNluxMEBidmRiRYLrNU8zKHCqb4PwbI9zgWyjdHnvcuKh NIfIe2UzPDVzOUe1NS=>
MIA MWXGeY5kfGmxbjDBd5NigQ>? MXuwMlUh|ryP MmTBNlQhcA>? MXzpcohq[mm2czDBb5QtKFN4S{GsJIFv\CCHcnuxM|IheGixc4Doc5J6dGG2aX;uxsA> MnT0NlQ2OTl5NUG=
AsPC-1 NXLpcJpiTnWwY4Tpc44hSXO|YYm= NHW4dGUxNjVizszN NUH3TWdEOjRiaB?= NVTlS5hZcW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi MmjDNlQ2OTl5NUG=
U87MG NUi3VlRFS2WubDDWbYFjcWyrdImgRZN{[Xl? MVewMVI2KM7:TR?= MWCyOE06PiCq M1fNRoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MmeyNlQxPjV3MkK=
SGC7901  M1LEb2Z2dmO2aX;uJGF{e2G7 NYnESnZvOC55NT:xNOKh|ryP NUPhbFBNPDhiaB?= Mm\p[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd|KTygdE1IW0t|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg NWDTZ29EOjN7MUKyOFY>
MGC803  MX3GeY5kfGmxbjDBd5NigQ>? NXLUclc{OC55NT:xNOKh|ryP MmTpOFjDqGh? NXrJe3Y1\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh MmHiNlM6OTJ{NE[=
TykNu MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6RVdKSzVyPUOuOUDPxE1? MnjjNlM5PzdyMUK=
TykNuR NF34WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLbmlEPTB;NT61JO69VQ>? NUX4bZQ2OjN6N{ewNVI>
M41 NIP6V2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\LOWlEPTB;MkSuO{DPxE1? MYOyN|g4PzBzMh?=
M41R MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Wz[2lEPTB;MUmuPEDPxE1? M1HMNlI{QDd5MEGy
OVCAR8 NWLs[3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HkZWlEPTB;M{GuNUDPxE1? M1W5SFI{QDd5MEGy
HeyA8 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPQcpRKSzVyPUK0MlMh|ryP MV:yN|g4PzBzMh?=
A2780CP M3XDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjVTWM2OD15Lk[g{txO NYnK[HplOjN6N{ewNVI>
OVCAR5 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZwNzFOwG0> MonlNlM5PzdyMUK=
A2780S MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[1UmlEPTB;MUSuOUDPxE1? M17pOFI{QDd5MEGy
MCAS M325cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrCO3NKSzVyPUGyMlUh|ryP NF7YSFQzOzh5N{CxNi=>
NCI-H727 MnLwR4VtdCCYaXHibYxqfHliQYPzZZk> MVmwMVExOCEQvF2= MUWyOE84OiCq MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M4rBUlIzPDl7NEO3
GOT1 NX;zdVlWS2WubDDWbYFjcWyrdImgRZN{[Xl? MX[wMVExOCEQvF2= M1LuUFI1Nzd{IHi= M{PVOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MV[yNlQ6QTR|Nx?=
BON1 MlL0R4VtdCCYaXHibYxqfHliQYPzZZk> MUOwMVExOCEQvF2= MYOyOE84OiCq NG\wS4Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWOyNlQ6QTR|Nx?=
BON1 NIe3emlCeG:ydH;zbZMhSXO|c3H5 MUWwMVExKM7:TR?= MW[yOEBp NIPCN2pqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 M1XVVVIzPDl7NEO3
BON1 NHrpU2RHfW6ldHnvckBCe3OjeR?= MVK3MlUwOTBizszN MmO2PEBp NIjrNWdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhfGinIHHueIku[XCxcITveIlkKHC{b4TlbY5{KEKFTEKgZY5lKEKlbD3YUC=> NIf4T3YzOjR7OUSzOy=>
Kasumi-1 NHLSVGFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWTBTnBmOC1{MDFOwG0> NXWzc5ZPOjRxNEigbC=> M33DboRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NXfETFhvOjJ2MEeyNlg>
HL-60 Mn7CR4VtdCCYaXHibYxqfHliQYPzZZk> M{nZTlAuOjBizszN NYnscnhCOjRxNEigbC=> Mljy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NWC2[XZIOjJ2MEeyNlg>
Kasumi-1 M2PFemFxd3C2b4Ppd{BCe3O|YYm= Mo[0NVAh|ryP MlW3NlQhcA>? NV;JTo9jcW6mdXPld{BieG:ydH;zbZM> M33Mc|IzPDB5MkK4
HL-60 MoLSRZBweHSxc3nzJGF{e3OjeR?= NXjjcm1iOTBizszN MoDTNlQhcA>? NYPscmx5cW6mdXPld{BieG:ydH;zbZM> Mnz0NlI1ODd{Mki=
Kasumi-1 NF;ucpVHfW6ldHnvckBCe3OjeR?= MUOyMlUwPS9zMDFOwG0> MVKyOEBp M{G3PIRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? NYrWcXY5OjJ2MEeyNlg>
HL-60 NHW0NGpHfW6ldHnvckBCe3OjeR?= MVeyMlUwPS9zMDFOwG0> MlTINlQhcA>? M{nLcoRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? Mn7kNlI1ODd{Mki=
Kasumi-1 NVzmSo9CTnWwY4Tpc44hSXO|YYm= NIDLO44zNjVxNT:xNEDPxE1? M{PVR|I1KGh? M3[4Xolv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MYWyNlQxPzJ{OB?=
HL-60 M4TWWWZ2dmO2aX;uJGF{e2G7 M1KxXVIvPS93L{GwJO69VQ>? M4qxUlI1KGh? MmXVbY5lfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqQS{GvNkBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M1[0c|IzPDB5MkK4
K562 NWnLOIVwTnWwY4Tpc44hSXO|YYm= MXmyNEDPxE1? MVO0PEBp NXTBbYw5cW6mdXPld{BifXSxcHjh[5nDqA>? NVP5SXhMOjJ2MEeyNlg>
OCUT1 NWfLeXljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjxUmd4OC5zLUOg{txO NWXMNVBPPSCm MmL6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MoHONlIxQTB{N{G=
K1 NVLkUYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\JNE4yNTNizszN NEn5T2s2KGR? M{i0dolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGTkbm8zOjB7MEK3NS=>
OCUT1 NEXGW|VHfW6ldHnvckBCe3OjeR?= M3K4NlMh|ryv NYW2TGl[OjRiaB?= NGewS3dk[XW|ZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBqdiCJMj;NJJBp[XOn MV2yNlA6ODJ5MR?=
CaOV3 NY\aXnZtS2WubDDWbYFjcWyrdImgRZN{[Xl? NWLCVHJROS93L{GwJO69VQ>? Mli5OFghcA>? NGjk[oNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYKgZ491emWjdHXkJJdqfGhicHHjcIl1[XinbB?= NE\tNFUzOTd5NUC1OC=>
SKOV3 MWTDfZRwfG:6aXPpeJkhSXO|YYm= NXz4[Y9XPSEQvF2= NUfUe2xzPDhiaB?= M4fVOIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M3XJNFIyPzd3MEW0
A2780 NFf2SXdEgXSxdH;4bYNqfHliQYPzZZk> MUK1JO69VQ>? NGfKNYo1QCCq MnvF[Y5p[W6lZYOgdIFkdGm2YYjlcEBqdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> NG\2ZVEzOTd5NUC1OC=>
HT-29  MW\DfZRwfG:6aXPpeJkhSXO|YYm= MX21JO69VQ>? MYC0PEBp M3vNcIVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NH3GcpAzOTd5NUC1OC=>
A498 NY\nOplVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTMS4kzOC12MDFOwG0> NGPUO4U4OiCq NUnMbphGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIrEZ|QzOTZ2NEC1NC=>
CAKI-1 NIm2[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn32NE01OCEQvF2= MXO3NkBp MUTJR|UxhjFyIN88US=> MnnqNlE3PDRyNUC=
769-P NGHrWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zjWVAuPDBizszN NYPxOFVtPzJiaB?= MV3JR|UxhjVvMUCg{txO MViyNVY1PDB3MB?=
786-0 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[wMVQxKM7:TR?= M{G5OFczKGh? NFXESIVKSzVyfkWg{txO NYHvVZNFOjF4NESwOVA>
786-O Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWwMVIxKM7:TR?= NWrBZlVPPzJiaB?= MYXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M2f3Z|IyPjR2MEWw
CAKI-1 NUmzRXpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPQWoIxNTJyIN88US=> NFnTc3U4OiCq MnOybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmTlNlE3PDRyNUC=
769-P MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPNflgxNTJyIN88US=> MXe3NkBp NHjqRWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWT4R2Q6OjF4NESwOVA>
A498 MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr4UGNSOC1{MDFOwG0> MXO3NkBp Mmq5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mlq4NlE3PDRyNUC=
CWR22RV1 MoDIR4VtdCCYaXHibYxqfHliQYPzZZk> NXO1W2JqOTBizszN NGDEdVkzPCCq MWjpcoNz\WG|ZYOgd4Vve2m2aY\peJkhd2ZiaIXtZY4hS1eUMkLSWlEh[2WubIOgeI8hemGmaXH0bY9v MmTiNlE1QTZ{N{O=
CWR22RV1 MkPkRZBweHSxc3nzJGF{e3OjeR?= M3L4clExKM7:TR?= NYrUU5NtOjRiaB?= M1nHe4VvcGGwY3XzJJJi\GmjdHnvckBqdmS3Y3XkJIFxd3C2b4Ppdy=> Mo\hNlE1QTZ{N{O=
CWR22RV1 M3\3cmZ2dmO2aX;uJGF{e2G7 NGrmTHI2KM7:TR?= NWLaZmQyOjRiaB?= NH;XbmFz\WS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Ric3nncolncWOjboTsfS=> MXGyNVQ6PjJ5Mx?=
HepG2  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjYSWlEPS9zMD:yNE81OCEQvF2= NWrUR|ZzOjRxNEivO|IhcA>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MXeyNFg1OjR{NR?=
Bel-7402 M1i2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjrWJFGPS9zMD:yNE81OCEQvF2= NFLDfpYzPC92OD:3NkBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NWD4WWhXOjB6NEK0NlU>
HepG2  NEm4fGJHfW6ldHnvckBCe3OjeR?= NUXOb4hlPS9zMD:yNEDPxE1? M3:0TlI1KGh? MU\y[ZN2dHS|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V? MmLKNlA5PDJ2MkW=
Bel-7402 NUDY[WN3TnWwY4Tpc44hSXO|YYm= M2TrOlUwOTBxMkCg{txO NXTKVZpCOjRiaB?= NInZU5Rz\XO3bITzJIlvKHSqZTDhZ4N2dXWuYYTpc44hd2ZiY3XscEBvfW2kZYKgbY4hfGinIFeyM20heGijc3W= NUTxNVh2OjB6NEK0NlU>
HepG2  M{ntO2Fxd3C2b4Ppd{BCe3O|YYm= Ml3jOU8yOC9{MDFOwG0> MoPUNlQwPDhiaB?= NYiwWpZYcW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> MV:yNFg1OjR{NR?=
Bel-7402 NGnFcpJCeG:ydH;zbZMhSXO|c3H5 M1POb|UwOTBxMkCg{txO NH;iNlUzPC92ODDo NUS1fYVvcW6mdXPld{BieG:ydH;zbZMh[XRidHjlJIxwdmdvdHnt[UBmgHCxc4Xy[S=> NEPDU|IzODh2MkSyOS=>
OAW-42 NHv2ZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHT1Z|MxNTRyIN88US=> NGqyeYI4OsLiaB?= M4\2WGlEPTC-MUCg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1Xve|IxPDB3Mkm2
PA-1  NHfi[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17zSFAuPDBizszN MXu3NuKhcA>? M{f6eGlEPTC-MkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX3jNWdiOjB2MEWyPVY>
SKOV3  MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:wMVQxKM7:TR?= NISyNnc4OsLiaB?= NXLJSIFPUUN3MI6zNEDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M3faR|IxPDB3Mkm2
A2780 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXJNE0zOCEQvF2= NXLPdohIPDhxN{KgbC=> NEDp[|BKSzVywrC9xsA{yqEQvH2= NHTsbXczODRyNUK5Oi=>
A2780cis  NH3ofnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf2NE0zOCEQvF2= NHj0fVM1QC95MjDo NVHmZ41kUUN3MNMgQeKhPsLizszt NHW2eoUzODRyNUK5Oi=>
SKW6.4 NYnWUnBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\hcYVUOi1zMNMg{txO MUi0POKhcA>? Mk\UbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MofYNlAyOzB7NkC=
MAVER MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNd4RlOi1zMNMg{txO Mlu1OFjDqGh? NYHJcZNncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MojrNlAyOzB7NkC=
BJAB NVXa[olIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGyMVExyqEQvF2= M1vmPVQ5yqCq M4XO[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M2L1fFIxOTNyOU[w
OCI MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiyMVExyqEQvF2= M1nuSVQ5yqCq MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NE\QUnozODF|MEm2NC=>
MOLM MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rI[FIuOTEEoN88US=> M2q2clQ5yqCq Mn3ibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHz4NVgzODF|MEm2NC=>
HL-60 NW\E[I5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnBbZgzNTFywrFOwG0> NG\qU241QMLiaB?= NY\UTJFjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mk\qNlAyOzB7NkC=
SKW6.4 NX7zW5lPSXCxcITvd4l{KEG|c4PhfS=> M3X2WFExyqEQvF2= MViyOE81QCCq MmTQbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= NF3r[HgzODF|MEm2NC=>
MAVER M1zRPWFxd3C2b4Ppd{BCe3O|YYm= NFjabYUyOMLizszN M3rjVVI1NzR6IHi= MXjpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 M2rSb|IxOTNyOU[w
BJAB MV;BdI9xfG:|aYOgRZN{e2G7 MXKxNOKh|ryP MmPoNlQwPDhiaB?= NXrlWFBVcW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> NWj0fJdiOjBzM{C5OlA>
OCI NYjDNHVlSXCxcITvd4l{KEG|c4PhfS=> M1\6bFExyqEQvF2= MmrqNlQwPDhiaB?= M4HH[olv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MX[yNFE{ODl4MB?=
MOLM M2fqV2Fxd3C2b4Ppd{BCe3O|YYm= M4fTNlExyqEQvF2= MUOyOE81QCCq NFjDOYtqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 M2qxV|IxOTNyOU[w
HL-60 NHi1SnhCeG:ydH;zbZMhSXO|c3H5 MnjJNVDDqM7:TR?= NELlR2gzPC92ODDo Mn\BbY5lfWOnczDhdI9xfG:|aYOgeIlu\S2mZYDlcoRmdnSueR?= NFTBV24zODF|MEm2NC=>

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID